208176-31-2Relevant articles and documents
SUBSTITUTED BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
-
Page/Page column 66, (2014/10/29)
The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.
Impact of electronic modification of the chelating benzylidene ligand in cis-dichloro-configured second-generation olefin metathesis catalysts on their activity
Pump, Eva,Poater, Albert,Zirngast, Michaela,Torvisco, Ana,Fischer, Roland,Cavallo, Luigi,Slugovc, Christian
supporting information, p. 2806 - 2813 (2014/06/24)
A series of electronically modified second-generation cis-dichloro ruthenium ester chelating benzylidene complexes was prepared, characterized, and benchmarked in a typical ring-opening metathesis polymerization (ROMP) experiment. The electronic tuning of the parent chelating benzylidene ligand (2-ethyl ester benzylidene) was achieved by substitution at the 4- and 5-positions with electron-withdrawing nitro or electron-donating methoxy groups. The effect of the electronic tuning on the cis-trans isomerization process was studied experimentally and theoretically. Density functional theory calculations clearly revealed the influence of electronic modification on the relative stability between the cis and trans isomers, which is decisive for the activity of the studied compounds as initiators in ROMP.
Benzamidoaldehydes and their use as cysteine protease inhibitors
-
, (2008/06/13)
Compounds of the formula where R1, R2, R3, X and n are as defined in the description, are inhibitors of cysteine protease.